Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABT 
Abbott Laboratories (ABT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: ABT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $144.43
1 Year Target Price $144.43
| 12 | Strong Buy |
| 7 | Buy |
| 9 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.78% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 224.35B USD | Price to earnings Ratio 16.17 | 1Y Target Price 144.43 |
Price to earnings Ratio 16.17 | 1Y Target Price 144.43 | ||
Volume (30-day avg) 28 | Beta 0.72 | 52 Weeks Range 109.21 - 139.33 | Updated Date 11/30/2025 |
52 Weeks Range 109.21 - 139.33 | Updated Date 11/30/2025 | ||
Dividends yield (FY) 1.84% | Basic EPS (TTM) 7.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 31.88% | Operating Margin (TTM) 19.4% |
Management Effectiveness
Return on Assets (TTM) 6.79% | Return on Equity (TTM) 30.62% |
Valuation
Trailing PE 16.17 | Forward PE 22.68 | Enterprise Value 229348593968 | Price to Sales(TTM) 5.12 |
Enterprise Value 229348593968 | Price to Sales(TTM) 5.12 | ||
Enterprise Value to Revenue 5.23 | Enterprise Value to EBITDA 19.47 | Shares Outstanding 1738871947 | Shares Floating 1728664769 |
Shares Outstanding 1738871947 | Shares Floating 1728664769 | ||
Percent Insiders 0.54 | Percent Institutions 81.18 |
Upturn AI SWOT
Abbott Laboratories
Company Overview
History and Background
Abbott Laboratories was founded in 1888 by Dr. Wallace Calvin Abbott in Chicago. Initially focusing on developing accurate dosages of known medicines, it has grown into a global healthcare leader through innovation, acquisitions, and a commitment to improving lives.
Core Business Areas
- Medical Devices: Develops and manufactures a wide range of medical devices, including cardiovascular devices, neuromodulation devices, and diabetes care products.
- Diagnostics: Offers a variety of diagnostic systems and tests used in hospitals, laboratories, and physician offices.
- Nutrition: Provides nutritional products for infants, children, and adults, including formulas, nutritional supplements, and medical nutrition products.
- Established Pharmaceuticals: Markets generic pharmaceuticals in developing countries.
Leadership and Structure
Robert B. Ford serves as Chairman and Chief Executive Officer. Abbott operates with a decentralized organizational structure, with each business segment having its own leadership and operations.
Top Products and Market Share
Key Offerings
- FreeStyle Libre: A continuous glucose monitoring (CGM) system for people with diabetes. Competitors include Dexcom (DXCM) and Medtronic (MDT). Market share varies by region, but FreeStyle Libre holds a significant portion of the global CGM market. Revenue from FreeStyle Libre represents a substantial portion of Abbott's medical device sales.
- Similac: A brand of infant formula. Competitors include Nestle (NSRGY) and Reckitt Benckiser (RBGLY). Similac holds a significant portion of the global infant formula market. Recent recalls have impacted market share.
- Alinity: A family of diagnostic systems for clinical chemistry, immunoassay, and blood and plasma screening. Competitors include Roche (RHHBY) and Siemens Healthineers. Abbott is gaining ground with Alinity.
- Ensure: Nutritional shake for adults. Abbott is the top player within the USA.
Market Dynamics
Industry Overview
The healthcare industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Demand for medical devices, diagnostics, and nutritional products continues to rise.
Positioning
Abbott Laboratories is a leading diversified healthcare company with a strong global presence. Its competitive advantages include a broad product portfolio, established brands, strong R&D capabilities, and global distribution network.
Total Addressable Market (TAM)
The global healthcare market is estimated to be trillions of USD. Abbott Laboratories addresses significant portions of this TAM across its various segments. Abbott is well-positioned to capture a larger share of its segments by investing in research and development, expanding its product portfolio, and strengthening its global distribution network.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong global presence
- Established brands
- Robust R&D capabilities
- Strong cash flow generation
Weaknesses
- Product recalls and supply chain vulnerabilities
- Dependence on key products
- Exposure to currency fluctuations
Opportunities
- Expanding into emerging markets
- Developing innovative products and technologies
- Acquiring complementary businesses
- Increasing demand for personalized medicine
Threats
- Intense competition
- Price pressures
- Regulatory changes
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- DHR
- BSX
- RHHBY
- MDT
Competitive Landscape
Abbott competes with other large healthcare companies on the basis of product innovation, quality, price, and distribution. Abbott's diversified portfolio and global reach provide a competitive advantage.
Major Acquisitions
St. Jude Medical
- Year: 2017
- Acquisition Price (USD millions): 25000
- Strategic Rationale: Expanded Abbott's cardiovascular device portfolio.
Growth Trajectory and Initiatives
Historical Growth: Abbott has experienced consistent growth over the past several years, driven by new product launches, acquisitions, and expansion into emerging markets.
Future Projections: Analysts project continued growth for Abbott, driven by increasing demand for its products and services, particularly in the areas of medical devices and diagnostics. Expected average revenue growth is around 5-7% annually.
Recent Initiatives: Recent strategic initiatives include investments in R&D, acquisitions of companies in complementary areas, and expansion into emerging markets.
Summary
Abbott is a strong, diversified healthcare company with a leading market position across various segments. The company's broad product portfolio and global reach provide a competitive advantage. However, Abbott faces challenges such as increasing competition and regulatory hurdles. The company's long-term growth prospects remain positive due to the increasing demand for healthcare products and services worldwide.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Abbott Laboratories Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Company Press Releases
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary by source. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange NYSE | Headquaters North Chicago, IL, United States | ||
IPO Launch date 1978-01-13 | Chairman of the Board, President & CEO Mr. Robert B. Ford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 114000 | Website https://www.abbott.com |
Full time employees 114000 | Website https://www.abbott.com | ||
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.